Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2016-11-01

AUTHORS

Hayley Bennett, Jason Gordon, Beverley Jones, Thomas Ward, Samantha Webster, Anupama Kalsekar, Yong Yuan, Michael Brenner, Phil McEwan

ABSTRACT

BackgroundHepatitis C virus (HCV) treatment can reduce the incidence of future infections through removing opportunities for onward transmission. This benefit is not captured in conventional cost-effectiveness evaluations of treatment and is particularly relevant in patient groups with a high risk of transmission, such as those people who inject drugs (PWID), where the treatment rates have been historically low. This study aimed to quantify how reduced HCV transmission changes the cost-effectiveness of new direct-acting antiviral (DAA) regimens as a function of treatment uptake rates.MethodsAn established model of HCV disease transmission and progression was used to quantify the impact of treatment uptake (10–100%), within the PWID population, on the cost-effectiveness of a DAA regimen versus pre-DAA standard of care, conducted using daclatasvir plus sofosbuvir in the UK setting as an illustrative example.ResultsThe consequences of reduced disease transmission due to treatment were associated with additional net monetary benefit of £24,304–£90,559 per patient treated at £20,000/QALY, when 10–100% of eligible patients receive treatment with 100% efficacy. Dependent on patient genotype, the cost-effectiveness of HCV treatment using daclatasvir plus sofosbuvir improved by 36–79% versus conventional analysis, at 10–100% treatment uptake in the PWID population.ConclusionsThe estimated cost-effectiveness of HCV treatment was shown to improve as more patients are treated, suggesting that the value of DAA regimens to the NHS could be enhanced by improved treatment uptake rates among PWID. However, the challenge for the future will lie in achieving increased rates of treatment uptake, particularly in the PWID population. More... »

PAGES

1001-1011

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10198-016-0844-8

DOI

http://dx.doi.org/10.1007/s10198-016-0844-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1030459780

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/27803989


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antiviral Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hepatitis C", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Incidence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Substance Abuse, Intravenous", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "HEOR, Health Economics and Outcomes Research Ltd, 9 Oak Tree Court, Mulberry Drive, Cardiff Gate Business Park, CF23 8RS, Cardiff, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "HEOR, Health Economics and Outcomes Research Ltd, 9 Oak Tree Court, Mulberry Drive, Cardiff Gate Business Park, CF23 8RS, Cardiff, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bennett", 
        "givenName": "Hayley", 
        "id": "sg:person.01364465020.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364465020.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Public Health, University of Adelaide, Adelaide, Australia", 
          "id": "http://www.grid.ac/institutes/grid.1010.0", 
          "name": [
            "HEOR, Health Economics and Outcomes Research Ltd, 9 Oak Tree Court, Mulberry Drive, Cardiff Gate Business Park, CF23 8RS, Cardiff, UK", 
            "Department of Public Health, University of Adelaide, Adelaide, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gordon", 
        "givenName": "Jason", 
        "id": "sg:person.01171526060.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171526060.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "HEOR, Health Economics and Outcomes Research Ltd, 9 Oak Tree Court, Mulberry Drive, Cardiff Gate Business Park, CF23 8RS, Cardiff, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "HEOR, Health Economics and Outcomes Research Ltd, 9 Oak Tree Court, Mulberry Drive, Cardiff Gate Business Park, CF23 8RS, Cardiff, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jones", 
        "givenName": "Beverley", 
        "id": "sg:person.016607167115.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016607167115.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "HEOR, Health Economics and Outcomes Research Ltd, 9 Oak Tree Court, Mulberry Drive, Cardiff Gate Business Park, CF23 8RS, Cardiff, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "HEOR, Health Economics and Outcomes Research Ltd, 9 Oak Tree Court, Mulberry Drive, Cardiff Gate Business Park, CF23 8RS, Cardiff, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ward", 
        "givenName": "Thomas", 
        "id": "sg:person.01003353464.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01003353464.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "HEOR, Health Economics and Outcomes Research Ltd, 9 Oak Tree Court, Mulberry Drive, Cardiff Gate Business Park, CF23 8RS, Cardiff, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "HEOR, Health Economics and Outcomes Research Ltd, 9 Oak Tree Court, Mulberry Drive, Cardiff Gate Business Park, CF23 8RS, Cardiff, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Webster", 
        "givenName": "Samantha", 
        "id": "sg:person.01165715264.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165715264.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "World Wide Health Economics and Outcomes Research, Bristol-Myers Squibb Pharmaceuticals Ltd, Princeton, USA", 
          "id": "http://www.grid.ac/institutes/grid.419971.3", 
          "name": [
            "World Wide Health Economics and Outcomes Research, Bristol-Myers Squibb Pharmaceuticals Ltd, Princeton, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kalsekar", 
        "givenName": "Anupama", 
        "id": "sg:person.01247570417.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01247570417.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "World Wide Health Economics and Outcomes Research, Bristol-Myers Squibb Pharmaceuticals Ltd, Princeton, USA", 
          "id": "http://www.grid.ac/institutes/grid.419971.3", 
          "name": [
            "World Wide Health Economics and Outcomes Research, Bristol-Myers Squibb Pharmaceuticals Ltd, Princeton, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yuan", 
        "givenName": "Yong", 
        "id": "sg:person.01253410531.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01253410531.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "UK HEOR, Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "UK HEOR, Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Brenner", 
        "givenName": "Michael", 
        "id": "sg:person.01234030464.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234030464.96"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "School of Human and Health Sciences, Swansea University, Swansea, UK", 
          "id": "http://www.grid.ac/institutes/grid.4827.9", 
          "name": [
            "HEOR, Health Economics and Outcomes Research Ltd, 9 Oak Tree Court, Mulberry Drive, Cardiff Gate Business Park, CF23 8RS, Cardiff, UK", 
            "School of Human and Health Sciences, Swansea University, Swansea, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McEwan", 
        "givenName": "Phil", 
        "id": "sg:person.01346767345.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346767345.38"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s40258-012-0002-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008579116", 
          "https://doi.org/10.1007/s40258-012-0002-0"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2016-11-01", 
    "datePublishedReg": "2016-11-01", 
    "description": "BackgroundHepatitis C virus (HCV) treatment can reduce the incidence of future infections through removing opportunities for onward transmission. This benefit is not captured in conventional cost-effectiveness evaluations of treatment and is particularly relevant in patient groups with a high risk of transmission, such as those people who inject drugs (PWID), where the treatment rates have been historically low. This study aimed to quantify how reduced HCV transmission changes the cost-effectiveness of new direct-acting antiviral (DAA) regimens as a function of treatment uptake rates.MethodsAn established model of HCV disease transmission and progression was used to quantify the impact of treatment uptake (10\u2013100%), within the PWID population, on the cost-effectiveness of a DAA regimen versus pre-DAA standard of care, conducted using daclatasvir plus sofosbuvir in the UK setting as an illustrative example.ResultsThe consequences of reduced disease transmission due to treatment were associated with additional net monetary benefit of \u00a324,304\u2013\u00a390,559 per patient treated at \u00a320,000/QALY, when 10\u2013100% of eligible patients receive treatment with 100% efficacy. Dependent on patient genotype, the cost-effectiveness of HCV treatment using daclatasvir plus sofosbuvir improved by 36\u201379% versus conventional analysis, at 10\u2013100% treatment uptake in the PWID population.ConclusionsThe estimated cost-effectiveness of HCV treatment was shown to improve as more patients are treated, suggesting that the value of DAA regimens to the NHS could be enhanced by improved treatment uptake rates among PWID. However, the challenge for the future will lie in achieving increased rates of treatment uptake, particularly in the PWID population.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10198-016-0844-8", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1297512", 
        "issn": [
          "1439-3972", 
          "1439-6637"
        ], 
        "name": "The European Journal of Health Economics", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "8", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "18"
      }
    ], 
    "keywords": [
      "treatment uptake rates", 
      "treatment uptake", 
      "PWID population", 
      "HCV treatment", 
      "HCV disease transmission", 
      "disease transmission", 
      "cost-effectiveness evaluation", 
      "DAA regimen", 
      "eligible patients", 
      "HCV transmission", 
      "acting antivirals", 
      "more patients", 
      "antiviral therapy", 
      "patient group", 
      "net monetary benefit", 
      "virus treatment", 
      "high risk", 
      "onward transmission", 
      "patient's genotype", 
      "future infections", 
      "treatment rates", 
      "patients", 
      "treatment", 
      "daclatasvir", 
      "sofosbuvir", 
      "population", 
      "uptake", 
      "regimen", 
      "PWID", 
      "therapy", 
      "antivirals", 
      "infection", 
      "incidence", 
      "QALY", 
      "progression", 
      "methodsAn", 
      "care", 
      "rate", 
      "efficacy", 
      "drugs", 
      "risk", 
      "transmission", 
      "DAA", 
      "benefits", 
      "ConclusionsThe", 
      "NHS", 
      "uptake rate", 
      "group", 
      "monetary benefits", 
      "genotypes", 
      "study", 
      "evaluation", 
      "impact", 
      "people", 
      "DAA standard", 
      "UK", 
      "function", 
      "consequences", 
      "standards", 
      "analysis", 
      "challenges", 
      "values", 
      "conventional analysis", 
      "future", 
      "opportunities", 
      "model", 
      "example", 
      "illustrative example", 
      "BackgroundHepatitis C virus (HCV) treatment", 
      "C virus (HCV) treatment", 
      "conventional cost-effectiveness evaluations", 
      "additional net monetary benefit", 
      "value of DAA", 
      "Hepatitis C disease transmission", 
      "C disease transmission"
    ], 
    "name": "Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies", 
    "pagination": "1001-1011", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1030459780"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10198-016-0844-8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "27803989"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10198-016-0844-8", 
      "https://app.dimensions.ai/details/publication/pub.1030459780"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:26", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_687.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10198-016-0844-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10198-016-0844-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10198-016-0844-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10198-016-0844-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10198-016-0844-8'


 

This table displays all metadata directly associated to this object as RDF triples.

246 TRIPLES      22 PREDICATES      111 URIs      102 LITERALS      16 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10198-016-0844-8 schema:about N03329fe935864e09816e41d6b9f1bf4c
2 N0f767a0ac87547efa7841792a6b2d140
3 N19f0b25ef24c4b9182bc5c70bbfc453d
4 N29607a1d806a4aa3827b232ef43414eb
5 N3544f0ddc3e64e1dbc6c2ba6e0b143c8
6 N5912d9b2585e4d799ec34a9221624ebd
7 N7ccf1f06569b4cbba97863652bbf294e
8 Nacf6e74d125c4b1d8124a144168cbae1
9 Nc321bb8c34444547bb413edf8a267254
10 anzsrc-for:11
11 anzsrc-for:1117
12 schema:author N41cfab55d36a48fe9fae8f439df13b7d
13 schema:citation sg:pub.10.1007/s40258-012-0002-0
14 schema:datePublished 2016-11-01
15 schema:datePublishedReg 2016-11-01
16 schema:description BackgroundHepatitis C virus (HCV) treatment can reduce the incidence of future infections through removing opportunities for onward transmission. This benefit is not captured in conventional cost-effectiveness evaluations of treatment and is particularly relevant in patient groups with a high risk of transmission, such as those people who inject drugs (PWID), where the treatment rates have been historically low. This study aimed to quantify how reduced HCV transmission changes the cost-effectiveness of new direct-acting antiviral (DAA) regimens as a function of treatment uptake rates.MethodsAn established model of HCV disease transmission and progression was used to quantify the impact of treatment uptake (10–100%), within the PWID population, on the cost-effectiveness of a DAA regimen versus pre-DAA standard of care, conducted using daclatasvir plus sofosbuvir in the UK setting as an illustrative example.ResultsThe consequences of reduced disease transmission due to treatment were associated with additional net monetary benefit of £24,304–£90,559 per patient treated at £20,000/QALY, when 10–100% of eligible patients receive treatment with 100% efficacy. Dependent on patient genotype, the cost-effectiveness of HCV treatment using daclatasvir plus sofosbuvir improved by 36–79% versus conventional analysis, at 10–100% treatment uptake in the PWID population.ConclusionsThe estimated cost-effectiveness of HCV treatment was shown to improve as more patients are treated, suggesting that the value of DAA regimens to the NHS could be enhanced by improved treatment uptake rates among PWID. However, the challenge for the future will lie in achieving increased rates of treatment uptake, particularly in the PWID population.
17 schema:genre article
18 schema:inLanguage en
19 schema:isAccessibleForFree false
20 schema:isPartOf N2310662ece3b4bb0beba3dca8d1b69e5
21 Nc31eef586fa24d66860ef358d17f7839
22 sg:journal.1297512
23 schema:keywords BackgroundHepatitis C virus (HCV) treatment
24 C disease transmission
25 C virus (HCV) treatment
26 ConclusionsThe
27 DAA
28 DAA regimen
29 DAA standard
30 HCV disease transmission
31 HCV transmission
32 HCV treatment
33 Hepatitis C disease transmission
34 NHS
35 PWID
36 PWID population
37 QALY
38 UK
39 acting antivirals
40 additional net monetary benefit
41 analysis
42 antiviral therapy
43 antivirals
44 benefits
45 care
46 challenges
47 consequences
48 conventional analysis
49 conventional cost-effectiveness evaluations
50 cost-effectiveness evaluation
51 daclatasvir
52 disease transmission
53 drugs
54 efficacy
55 eligible patients
56 evaluation
57 example
58 function
59 future
60 future infections
61 genotypes
62 group
63 high risk
64 illustrative example
65 impact
66 incidence
67 infection
68 methodsAn
69 model
70 monetary benefits
71 more patients
72 net monetary benefit
73 onward transmission
74 opportunities
75 patient group
76 patient's genotype
77 patients
78 people
79 population
80 progression
81 rate
82 regimen
83 risk
84 sofosbuvir
85 standards
86 study
87 therapy
88 transmission
89 treatment
90 treatment rates
91 treatment uptake
92 treatment uptake rates
93 uptake
94 uptake rate
95 value of DAA
96 values
97 virus treatment
98 schema:name Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies
99 schema:pagination 1001-1011
100 schema:productId N3a7159d134f54f66946c1cfaa4044e52
101 N78bbdae6b9f94d6895cf1c49ed6f32e8
102 Nddb882cc277d451185d35f5a056922fd
103 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030459780
104 https://doi.org/10.1007/s10198-016-0844-8
105 schema:sdDatePublished 2021-11-01T18:26
106 schema:sdLicense https://scigraph.springernature.com/explorer/license/
107 schema:sdPublisher N803a73fee9324cdd9f4b8f780e102f80
108 schema:url https://doi.org/10.1007/s10198-016-0844-8
109 sgo:license sg:explorer/license/
110 sgo:sdDataset articles
111 rdf:type schema:ScholarlyArticle
112 N03329fe935864e09816e41d6b9f1bf4c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Cost-Benefit Analysis
114 rdf:type schema:DefinedTerm
115 N0f767a0ac87547efa7841792a6b2d140 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Antiviral Agents
117 rdf:type schema:DefinedTerm
118 N19f0b25ef24c4b9182bc5c70bbfc453d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Humans
120 rdf:type schema:DefinedTerm
121 N2310662ece3b4bb0beba3dca8d1b69e5 schema:issueNumber 8
122 rdf:type schema:PublicationIssue
123 N28ae434e5b5c404fb29cbaa732b49dab rdf:first sg:person.01234030464.96
124 rdf:rest Ne0d78a559915488d8846904dc0fa9c1e
125 N29607a1d806a4aa3827b232ef43414eb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Substance Abuse, Intravenous
127 rdf:type schema:DefinedTerm
128 N3544f0ddc3e64e1dbc6c2ba6e0b143c8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Male
130 rdf:type schema:DefinedTerm
131 N3a7159d134f54f66946c1cfaa4044e52 schema:name doi
132 schema:value 10.1007/s10198-016-0844-8
133 rdf:type schema:PropertyValue
134 N3cf5fb64de214ec9b5a458e5c5de8e09 rdf:first sg:person.01165715264.65
135 rdf:rest Nc3e3544644fc4108b2c27c435be46051
136 N41cfab55d36a48fe9fae8f439df13b7d rdf:first sg:person.01364465020.33
137 rdf:rest Na068e8781c2f45868bcd3732c7b7b2d7
138 N5912d9b2585e4d799ec34a9221624ebd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Middle Aged
140 rdf:type schema:DefinedTerm
141 N78bbdae6b9f94d6895cf1c49ed6f32e8 schema:name dimensions_id
142 schema:value pub.1030459780
143 rdf:type schema:PropertyValue
144 N7ccf1f06569b4cbba97863652bbf294e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Hepatitis C
146 rdf:type schema:DefinedTerm
147 N803a73fee9324cdd9f4b8f780e102f80 schema:name Springer Nature - SN SciGraph project
148 rdf:type schema:Organization
149 Na068e8781c2f45868bcd3732c7b7b2d7 rdf:first sg:person.01171526060.18
150 rdf:rest Na30f4bad9ce94bc8abdf08e5ed45bfe2
151 Na30f4bad9ce94bc8abdf08e5ed45bfe2 rdf:first sg:person.016607167115.29
152 rdf:rest Nc8bee15de3d24afa946ef28e49187def
153 Nacf6e74d125c4b1d8124a144168cbae1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Incidence
155 rdf:type schema:DefinedTerm
156 Nc31eef586fa24d66860ef358d17f7839 schema:volumeNumber 18
157 rdf:type schema:PublicationVolume
158 Nc321bb8c34444547bb413edf8a267254 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Female
160 rdf:type schema:DefinedTerm
161 Nc3e3544644fc4108b2c27c435be46051 rdf:first sg:person.01247570417.25
162 rdf:rest Ne34454e5ed53437482872315b3b6db7f
163 Nc8bee15de3d24afa946ef28e49187def rdf:first sg:person.01003353464.51
164 rdf:rest N3cf5fb64de214ec9b5a458e5c5de8e09
165 Nddb882cc277d451185d35f5a056922fd schema:name pubmed_id
166 schema:value 27803989
167 rdf:type schema:PropertyValue
168 Ne0d78a559915488d8846904dc0fa9c1e rdf:first sg:person.01346767345.38
169 rdf:rest rdf:nil
170 Ne34454e5ed53437482872315b3b6db7f rdf:first sg:person.01253410531.33
171 rdf:rest N28ae434e5b5c404fb29cbaa732b49dab
172 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
173 schema:name Medical and Health Sciences
174 rdf:type schema:DefinedTerm
175 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
176 schema:name Public Health and Health Services
177 rdf:type schema:DefinedTerm
178 sg:journal.1297512 schema:issn 1439-3972
179 1439-6637
180 schema:name The European Journal of Health Economics
181 schema:publisher Springer Nature
182 rdf:type schema:Periodical
183 sg:person.01003353464.51 schema:affiliation grid-institutes:None
184 schema:familyName Ward
185 schema:givenName Thomas
186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01003353464.51
187 rdf:type schema:Person
188 sg:person.01165715264.65 schema:affiliation grid-institutes:None
189 schema:familyName Webster
190 schema:givenName Samantha
191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165715264.65
192 rdf:type schema:Person
193 sg:person.01171526060.18 schema:affiliation grid-institutes:grid.1010.0
194 schema:familyName Gordon
195 schema:givenName Jason
196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171526060.18
197 rdf:type schema:Person
198 sg:person.01234030464.96 schema:affiliation grid-institutes:None
199 schema:familyName Brenner
200 schema:givenName Michael
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234030464.96
202 rdf:type schema:Person
203 sg:person.01247570417.25 schema:affiliation grid-institutes:grid.419971.3
204 schema:familyName Kalsekar
205 schema:givenName Anupama
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01247570417.25
207 rdf:type schema:Person
208 sg:person.01253410531.33 schema:affiliation grid-institutes:grid.419971.3
209 schema:familyName Yuan
210 schema:givenName Yong
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01253410531.33
212 rdf:type schema:Person
213 sg:person.01346767345.38 schema:affiliation grid-institutes:grid.4827.9
214 schema:familyName McEwan
215 schema:givenName Phil
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346767345.38
217 rdf:type schema:Person
218 sg:person.01364465020.33 schema:affiliation grid-institutes:None
219 schema:familyName Bennett
220 schema:givenName Hayley
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364465020.33
222 rdf:type schema:Person
223 sg:person.016607167115.29 schema:affiliation grid-institutes:None
224 schema:familyName Jones
225 schema:givenName Beverley
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016607167115.29
227 rdf:type schema:Person
228 sg:pub.10.1007/s40258-012-0002-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008579116
229 https://doi.org/10.1007/s40258-012-0002-0
230 rdf:type schema:CreativeWork
231 grid-institutes:None schema:alternateName HEOR, Health Economics and Outcomes Research Ltd, 9 Oak Tree Court, Mulberry Drive, Cardiff Gate Business Park, CF23 8RS, Cardiff, UK
232 UK HEOR, Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, UK
233 schema:name HEOR, Health Economics and Outcomes Research Ltd, 9 Oak Tree Court, Mulberry Drive, Cardiff Gate Business Park, CF23 8RS, Cardiff, UK
234 UK HEOR, Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, UK
235 rdf:type schema:Organization
236 grid-institutes:grid.1010.0 schema:alternateName Department of Public Health, University of Adelaide, Adelaide, Australia
237 schema:name Department of Public Health, University of Adelaide, Adelaide, Australia
238 HEOR, Health Economics and Outcomes Research Ltd, 9 Oak Tree Court, Mulberry Drive, Cardiff Gate Business Park, CF23 8RS, Cardiff, UK
239 rdf:type schema:Organization
240 grid-institutes:grid.419971.3 schema:alternateName World Wide Health Economics and Outcomes Research, Bristol-Myers Squibb Pharmaceuticals Ltd, Princeton, USA
241 schema:name World Wide Health Economics and Outcomes Research, Bristol-Myers Squibb Pharmaceuticals Ltd, Princeton, USA
242 rdf:type schema:Organization
243 grid-institutes:grid.4827.9 schema:alternateName School of Human and Health Sciences, Swansea University, Swansea, UK
244 schema:name HEOR, Health Economics and Outcomes Research Ltd, 9 Oak Tree Court, Mulberry Drive, Cardiff Gate Business Park, CF23 8RS, Cardiff, UK
245 School of Human and Health Sciences, Swansea University, Swansea, UK
246 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...